E

Euroapi SAS
PAR:EAPI

Watchlist Manager
Euroapi SAS
PAR:EAPI
Watchlist
Price: 3.184 EUR -1.18% Market Closed
Market Cap: 304.4m EUR

Wall Street
Price Targets

EAPI Price Targets Summary
Euroapi SAS

Wall Street analysts forecast EAPI stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EAPI is 2.907 EUR with a low forecast of 2.525 EUR and a high forecast of 3.15 EUR.

Lowest
Price Target
2.525 EUR
21% Downside
Average
Price Target
2.907 EUR
9% Downside
Highest
Price Target
3.15 EUR
1% Downside
Euroapi SAS Competitors:
Price Targets
016580
Whanin Pharm Co Ltd
31% Upside
002294
Shenzhen Salubris Pharmaceuticals Co Ltd
2% Upside
LAURUSLABS
Laurus Labs Ltd
23% Downside
ZYDUSLIFE
Zydus Lifesciences Ltd
3% Upside
4528
Ono Pharmaceutical Co Ltd
6% Upside
600566
Hubei Jumpcan Pharmaceutical Co Ltd
24% Upside

Revenue
Forecast

Revenue Estimate
Euroapi SAS

For the last 4 years the compound annual growth rate for Euroapi SAS's revenue is -1%. The projected CAGR for the next 3 years is 0%.

-1%
Past Growth
0%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Euroapi SAS

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-67%
Average Miss

Net Income
Forecast

Net Income Estimate
Euroapi SAS

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EAPI's stock price target?
Price Target
2.907 EUR

According to Wall Street analysts, the average 1-year price target for EAPI is 2.907 EUR with a low forecast of 2.525 EUR and a high forecast of 3.15 EUR.

What is Euroapi SAS's Revenue forecast?
Projected CAGR
0%

For the last 4 years the compound annual growth rate for Euroapi SAS's revenue is -1%. The projected CAGR for the next 3 years is 0%.

Back to Top